同仁堂拟入主，嘉事堂今起复牌

Core Viewpoint - On February 2, 2023, the shareholders of Jiasitang, Guangda Industrial and Guangda Health, signed a share transfer agreement with Tongrentang Group, resulting in a change of controlling shareholder to Tongrentang Group and actual controller to the State-owned Assets Supervision and Administration Commission of Beijing Municipal Government [1][5]. Group 1: Share Transfer Details - Guangda Industrial and Guangda Health will transfer 41.18 million shares and 41.87 million shares of Jiasitang, respectively, for a total consideration of 1.461 billion yuan [1][5]. - The share transfer price is set at 17.59 yuan per share, with Guangda Health's share transfer accounting for 14.36% of the total share capital and Guangda Industrial's accounting for 14.12% [5]. - After the transaction, Tongrentang Group will hold a 28.48% stake, becoming the controlling shareholder [5]. Group 2: Regulatory Approvals - The share transfer is subject to approval from the relevant state-owned assets supervision authority, antitrust review by the State Administration for Market Regulation, compliance confirmation by the Shenzhen Stock Exchange, and registration with the China Securities Depository and Clearing Corporation [5]. - The completion of the transaction and its timing remain uncertain [5]. Group 3: Company Background and Performance - Jiasitang was established in 1997 and listed on the Shenzhen Stock Exchange in 2010, becoming a key platform for Guangda's health business in 2018 [6]. - The company’s main operations include sales to secondary and tertiary hospitals, community medical centers, logistics distribution, and retail, covering pharmaceuticals, biological products, medical devices, and traditional Chinese medicine [6]. - For the first three quarters of 2025, Jiasitang reported revenue of 14.46 billion yuan, a year-on-year decline of 21.8%, and a net profit attributable to shareholders of 141 million yuan, down 38.81% year-on-year [6].